Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Venglustat

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi’s Venglustat Earns BTD in US for Type 3 Gaucher Disease
    Sanofi’s Venglustat Earns BTD in US for Type 3 Gaucher Disease

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3257888/0/en/Press-Release-Sanofi-s-venglustat-earns-Breakthrough-Therapy-designation-in-the-US-for-type-3-Gaucher-disease.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Sanofi Rare Disease Drug Shows Success And Failure In Phase 3
    Sanofi Rare Disease Drug Shows Success And Failure In Phase 3

    02 Feb 2026

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947

    PRESS RELEASE
    02 Feb 2026
    Share Share
    Sanofi hit by filing delays for key drugs
    Sanofi hit by filing delays for key drugs

    29 Oct 2021

    // Ben Adams FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-hit-by-filing-delays-for-key-drugs-drops-early-sangamo-thalassemia-asset

    Ben Adams FIERCEBIOTECH
    29 Oct 2021
    Share Share
    Sanofi halts venglustat clinical programme in ADPKD
    Sanofi halts venglustat clinical programme in ADPKD

    02 Jun 2021

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/sanofi_halts_venglustat_clinical_programme_in_adpkd_1370973

    Lucy Parsons PHARMATIMES
    02 Jun 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.